Depakote
Product Images NDC 43353-310

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Depakote (NDC 43353-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 500mg (43353 310)

Bottle Label 500mg (43353 310)
This is a description of a medication named Divalproex NA (Depakote) ER. The medication comes in a package size of 28 tablets, each containing 500mg of medication. The manufacturing company is AbbVie LTD and the tablets are repackaged by Aphena Pharma. The medication should be stored at a temperature between 20-25 degrees Celsius.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure Of Divalproex Sodium (Depakote Er 01)

FDA Label Image

Figure 3 (Depakote Er 02)

Figure 3 (Depakote Er 02)
This looks like a table with some numerical values (12, 0.4, 0.2, and 0.6) followed by an asterisk and a significance value (p=0.006) and the names of two treatments (Placebo and Depakote ER). However, without any context or headings, it is not clear what this information relates to.*
FDA Label Image

Figure 1 (Depakote Er 03)

Figure 1 (Depakote Er 03)
This is a graphical representation of the reduction in CPS (complex partial seizures) rate for patients taking Depakote versus a placebo. The graph shows that 100% of patients taking Depakote showed an improvement in CPS rate compared to 50% of patients taking the placebo. The percentage reduction in CPS rate is not provided.*
FDA Label Image

Figure 2 (Depakote Er 04)

Figure 2 (Depakote Er 04)
This is a chart that shows the reduction in CPS (cycles per second) rate based on the dosage of DEPAKOTE, with high and low doses compared alongside the percentage of patients who experienced improvement, no change, or worsening symptoms.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.